Summit Therapeutics Inc. SMMT
Regular-session close
After hours · Nov 16, 7:59 PM ET
- YTD
- -32.42%
- 1 year
- -34.44%
- Market cap
- 9.45B
- EPS (ttm)
- -0.89
- Shares out
- 799.76M
- Forward P/E
- -11.18
- YTD return
- -32.42%
- 1-year return
- -34.44%
- 50-day average
- 16.41
- 200-day average
- 16.15
- Enterprise value
- 10.71B
- Price / book
- 16.74
- Volume
- 24.43M
- Avg volume
- 6.18M
- Open
- 12.68
- Previous close
- 14.15
- Day's range
- 11.53 – 13.28
- 52-week range
- 11.82 – 26.38
- Beta
- -1.52
- Analysts
- Buy
- Price target
- 29.28 (+147.7%)
- Earnings date
- Feb 22, 2027
5D -5.76 (-32.76%)
Key statistics
- Free cash flow
- -213.92M
- Total cash
- 629.79M
- Total debt
- 19.98M
- Return on equity
- -220.01%
- Short % of float
- 26.67%
Fundamental scorecard
5 of 25 checks passed on SMMT’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 11.69
- Target (mean)
- 29.28
- Target (high)
- 42.08
- Strong buy1
- Buy10
- Hold5
- Sell0
- Strong sell0
Next earnings
Feb 22, 2027
Expected Feb 22, 2027. Consensus EPS estimate -0.21125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 22, 2027 | Dec 30, 2026 | -0.34 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.28174 | -0.26 | +0.02 | +7.72% |
| Jul 23, 2026 | Jun 30, 2026 | -0.27439 | -0.28 | -0.01 | -2.04% |
| Apr 30, 2026 | Mar 31, 2026 | -0.33 | -0.24 | +0.09 | +27.27% |
| Feb 23, 2026 | Dec 31, 2025 | -0.10264 | -0.29 | -0.19 | -182.54% |
| Oct 20, 2025 | Sep 30, 2025 | -0.17577 | -0.31 | -0.13 | -76.37% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 16, 2026 | Citigroup | main | Buy | Buy |
| Nov 16, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Nov 16, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 1, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Sep 29, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- smmttx.com
News
Citigroup Maintains Buy on Summit Therapeutics, Lowers Price Target to $42
Summit Stock Falls on FDA Rejection for Lung Cancer Drug Barclays Maintains Equal-Weight on Summit Therapeutics, Lowers Price Target to $18
Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment Evercore ISI Group Maintains Outperform on Summit Therapeutics, Lowers Price Target to $33
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Fall as Scott Bessent Presses Nvidia Over China Chips — BIDU, RKLB, MSTR in Focus (UPDATED)
Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on SMMT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANAND BHASKAR | Officer | Stock Award(Grant) | Oct 7, 2026 | 261,047 |
| DUGGAN ROBERT WILLIAM | Chief Executive Officer | Purchase | Jun 11, 2026 | 610,016,000 |
| SONI MANMEET SINGH | Chief Operating Officer | Purchase | Jun 3, 2026 | 3,123,600 |
| XIA YU | Director | Purchase | Oct 20, 2025 | 0 |
| ZANGANEH MAHKAM | Chief Executive Officer | Purchase | Jun 11, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 4.10% | 32,786,348 | 387.53M | Jun 29, 2026 |
| Blackrock Inc. | 1.30% | 10,363,750 | 122.50M | Sep 29, 2026 |
| FMR, LLC | 1.02% | 8,136,745 | 96.18M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 0.90% | 7,230,441 | 85.46M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 0.84% | 6,717,642 | 79.40M | Sep 29, 2026 |
| State Street Corporation | 0.76% | 6,093,474 | 72.02M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.46% | 3,707,548 | 43.82M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 0.45% | 3,635,145 | 42.97M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.33% | 2,667,317 | 31.53M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.32% | 2,531,231 | 29.92M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.26% | 2,047,862 | 24.21M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.22% | 1,778,361 | 21.02M | Jun 29, 2026 |
